Clinical trial
UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.
NCT03224871
Study timeline
Study start (actual)2017-08-11Date precision: day
Registry last updated2020-04-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
METASTATIC NON-SMALL CELL LUNG CANCERunresolved
Interventions
NivolumabDRUG · verified · RxNorm: nivolumab
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
RadiotherapyRADIATION
Sponsors & collaborators
University of California, Davislead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03224871 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.